Rational design of triazololipopeptides analogs of kisspeptin inducing a long-lasting increase of gonadotropins

  • J Med Chem. 2015 Apr 23;58(8):3459-70. doi: 10.1021/jm5019675.
Massimiliano Beltramo  1 Vincent Robert  1 Mathieu Galibert  2 Jean-Baptiste Madinier  2 Philippe Marceau  2 Hugues Dardente  1 Caroline Decourt  1 Nicolas De Roux  3 Didier Lomet  1 Agnès F Delmas  2 Alain Caraty  1 Vincent Aucagne  2
Affiliations
  • 1. †UMR Physiologie de la Reproduction et des Comportements (INRA, UMR85; CNRS, UMR7247; Université François Rabelais Tours; IFCE), F-37380 Nouzilly, France.
  • 2. ‡Centre de Biophysique Moléculaire (CNRS UPR4301), Rue Charles Sadron, F-45071 Orléans Cedex 2, France.
  • 3. §INSERM U690, Hôpital Robert Debré, 75019 Paris, France.
Abstract

New potent and selective KISS1R agonists were designed using a combination of rational chemical modifications of the endogenous neuropeptide kisspeptin 10 (KP10). Improved resistance to degradation and presumably reduced renal clearance were obtained by introducing a 1,4-disubstituted 1,2,3-triazole as a proteolysis-resistant amide mimic and a serum albumin-binding motif, respectively. These triazololipopeptides are highly potent full agonists of KISS1R and are >100 selective over the closely related NPFF1R. When injected in ewes with a quiescent reproductive system, the best compound of our series induced a much prolonged increase of luteinizing hormone release compared to KP10 and increased follicle-stimulating hormone plasma concentration. Hence, this KISS1R agonist is a new valuable pharmacological tool to explore the potential of KP system in reproduction control. Furthermore, it represents the first step to develop drugs treating reproductive system disorders due to a reduced activity of the hypothalamo-pituitary-gonadal axis such as delayed puberty, hypothalamic amenorrhea, and hypogonadotropic hypogonadism.